Biorg Leadership
Biorg's team combines scientific expertise with deep curiosity, passion for collaboration, and commitment to scientific innovations that benefit society
Timothy R. Wright
CEO
Mr. Timothy R. Wright serves as CEO of Biorg. He is the Co-Founder and Chairman of Isosceles Pharmaceuticals, a pre-clinical stage pharmaceutical company developing intravenous formulations of a synthetic cannabidiol for the treatment of post operative pain. Additionally, Tim is the Founder of the Drug Development Institute at The Ohio State Comprehensive Cancer Center (https://cancer.osu.edu/for-cancer-researchers/research/research-institutes-and-centers/drug-development-institute) and Co-Founder of The Oncology Research Information Exchange Network (www.Oriencancer.org). Tim served as President and CEO of Mimedx and M2 Gen, EVP of TEVA Mergers and Acquisitions and Innovation, President of Covidien Mallinkrodt, Chief Operating Officer of Elan, SVP of Cardinal Health and Dupont Merck Pharmaceuticals. Additionally, Tim is on the Board of Directors of Agenus Bio and Protogenics.
Enoch Kim, PhD
CSO
Dr. Kim leads all research and development efforts at Biorg, from conception of ideas to planning and execution of product development. He is an interdisciplinary scientist with a proven record of innovation; he was trained in chemistry, engineered microfabricated devices and functional surfaces for advanced assays, and played a critical role in discovery and development of three Novel Chemical Entities (NCE) in metabolic, cardiovascular, and oncology indications. His research experience in drug discovery includes translational research in multiple therapeutic areas, as well as assay development and qualification for primary and secondary screening, preclinical pharmacology, preclinical ADME, medicinal chemistry, and IND-enabling preclinical development and drug manufacturing. He received a Ph.D. in Chemistry from Harvard University.